A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...

A new study led by researchers at the Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...

Acquisition of mesenchymal markers during ... Molecular characterization of CTCs and targeted therapies. Signaling pathways represented in CTCs regulating stem cells, proliferation and survival ...

Explore GISTs, rare GI tumors. Discover key details on genetic causes, diagnostic methods, and cutting-edge treatment ...

BrainStorm Cell Therapeutics Inc. , a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with leading ALS research centers, today announced the acceptance of new ...

S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a Phase 1b clinical ...

Netta Blondheim-Shraga, PhD, Senior Vice President of Research & Development at BrainStorm, will present new insights into ...

No refractures were reported during long-term follow-up at five yearsAt 24-months post-implantation, 89% of patients achieved bone unionNovadip plans market launch of NVD003 in 2027Mont Saint-Guibert, ...

Negative Breast Cancer Market Insight, Epidemiology and Market Forecast - 2035" report delivers comprehensive insights into triple-negative breast cancer, i ...